BBV154 is Bharat Biotech’s new intranasal vaccine for SARS-CoV-2. It was developed by Bharat Biotech in partnership with Washington University School of Medicine in St Louis. It is simple to administer and has no needle-associated risks. The first phase of the intranasal vaccine will be conducted in February-March of this year. This announcement came after the approval of Drug Controller General for Bharat Biotech’s Covaxin.

No comments yet.

Leave a Reply